Wall Street analysts forecast that CymaBay Therapeutics Inc (NASDAQ:CBAY) will announce ($0.12) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is $0.03 and the lowest is ($0.22). CymaBay Therapeutics reported earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 60%. The firm is expected to announce its next quarterly earnings report on Thursday, March 22nd.
On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($0.82) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.02) to ($0.82). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). During the same quarter in the prior year, the company posted ($0.25) earnings per share.
In related news, Director Kurt Von Emster sold 59,209 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $834,300. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Carl Goldfischer sold 18,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $8.66, for a total value of $155,880.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at $77,940. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 304,749 shares of company stock valued at $2,841,832. 15.10% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of CBAY. Perceptive Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $18,948,000. Citadel Advisors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $5,159,000. EAM Investors LLC bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $4,788,000. Omega Fund Management LLC raised its position in shares of CymaBay Therapeutics by 82.9% in the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after acquiring an additional 250,000 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of CymaBay Therapeutics in the 3rd quarter worth about $1,536,000. 69.12% of the stock is owned by hedge funds and other institutional investors.
Shares of CymaBay Therapeutics (NASDAQ CBAY) traded up $0.06 on Friday, hitting $10.20. The stock had a trading volume of 612,884 shares, compared to its average volume of 543,697. CymaBay Therapeutics has a one year low of $1.46 and a one year high of $10.50. The company has a market cap of $450.06, a PE ratio of -10.10 and a beta of 1.82. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.